Key Takeaway The Medicare GLP-1 Bridge program begins July 1, 2026, giving eligible Part D beneficiaries early access to Wegovy, Foundayo, and Zepbound KwikPen before full Part D weight-loss coverage arrives January 1, 2027
The CV safety of a lower dose of liraglutide (1.8 mg, Victoza, Novo Nordisk) in people with T2D was established in the Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results (LEADER) study, showing a 13% reduction in major CV events over an average of 3.8 years [44]
Cancer 149, 778789
Keep the Progress With a Real Maintenance Plan If you are preparing to maintain weight after GLP-1 treatment, Maryland Trim Clinic can help you build a plan before regain starts
Acta Endocrinol (1987) 114(4):497502
It's plausible, but unproven